Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

28 September 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicro..

26 September 2022

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorizat..

16 September 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® ..

Press releases (more)

Upcoming Events

November 7, 2022 at 8:00 AM EST

November 7, 2022: Third Quarter 2022 Earnings

November 15 - November 17, 2022

Jefferies 2022 London Healthcare Conference


November 29 - December 1, 2022

Evercore ISI’s HealthCONx Conference


Upcoming events (more)

Stock Quote

Oct 2, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.